Geri
FibroGen Inc (FGEN) Fiyatı
FGEN Hisse Senedi Fiyat Grafiği
FGEN Kazanmak
FibroGen Inc
$8.74
-2.56%
$-0.23
Kapanışta: Jan 23, 16:00:00 GMT-5
$8.74
0%
$0
Sonrası Piyasa: Jan 23, 20:00:00 GMT-5
Henüz Veri YokEarnings FAQ
FGEN'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
FibroGen Inc FGEN'ün son çeyrekteki geliri nasıl performans gösterdi?
FibroGen Inc'in gelir tahmini nedir?
FibroGen Inc'in kazanç kalite puanı nedir?
FibroGen Inc kazançlarını ne zaman rapor eder?
FibroGen Inc'in beklenen kazançları nelerdir?
FibroGen Inc kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$8.97
Açılış fiyatı
$9
Günün Aralığı
$8.56 - $9.08
52 haftalık aralık
$4.85 - $21.93
İşlem hacmi
--
Ort.Hacim
33.1K
EPS (TTM)
-0.52
Dividend yield
--
Piyasa Değeri
$35.3M
FGEN nedir?
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved